Skip to main content

Table 3 Audit outcomes for interventions to prevent infections

From: Adherence to guidelines across different specialties to prevent infections in patients undergoing immunosuppressive therapies

 Dermatology [n = 38]Gastroenterolgy [n = 42]Haematology [n = 30]Nephrology [n = 45]Rheumatology [n = 49]Combined population [n = 204]
Tuberculosis screening, n[%]
 Pre-treatment discussion37 [97]40 [93]3 [10]1 [4]27 [57]70 [34]
 Pre-treatment chest x-ray33 [87]37 [88]25 [83]40 [89]37 [76]172 [84]
 IGRAa30 [79]34 [81]1 [3]4 [9]23 [47]90 [45]
Blood-borne virus screening, n[%]
 HIV16 [42]36 [84]19 [63]39 [87]4 [8]114 [56]
 Hepatitis B [HBsAg]35 [92]34 [81]19 [63]38 [84]30 [61]156 [76]
 Hepatitis B exposure [HBcAb]0 [0]4 [10]12 [40]20 [44]4 [8]40 [20]
 Hepatitis B immunity [HBsAb]0 [0]3 [8]3 [10]8 [18]1 [2]15 [7]
 Hepatitis C35 [9235 [83]18 [60]39 [87]29 [59]156 [76]
Other viral immunity screen, n[%]
 Varicella zoster immunity37 [97]26 [62]6 [20]23 [52]33 [67]133 [65]
 Measles immunity14 [38]41 [98]8 [27]38 [84]3 [6]104 [51]
Hypogammaglobulinaemia screen, n[%]4 [11]1 [2]23 [78]21 [48]32 [65]81 [40]
Immunisation advice, n[%]
 Influenza38 [100]37 [88]23 [78]0 [0]49 [100]148 [73]
 Pneumococcalb0 [0]37 [88]0 [0]0 [0]7 [15]44 [22]
 Varicella zoster [if non-immune]1 [25]1 [20]0 [0]0 [0]2 [50]4 [30]
 Hepatitis B [if non-immune]0 [0]0 [0]0 [0]1 [50]0 [0]1 [33]
Discussions on infection risk, n[%]
 General infection risks38 [100]38 [90]22 [75]45 [100]48 [98]191 [94]
 Live vaccine risk38 [100]37 [88]23 [78]45 [100]49 [100]192 [94]
Provision of PJP prophylaxisc, n[%]1/23 [4]3/22 [14]36/40 [90]0/19 [0]40/104 [38]
  1. aIGRA: interferon-gamma release assay; b either PPV-23 or PCV-13; c in those receiving potent immunosuppression